GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00083809 | Breast | Precancer | RNA splicing | 65/1080 | 434/18723 | 1.27e-12 | 2.53e-10 | 65 |
GO:00434849 | Breast | Precancer | regulation of RNA splicing | 34/1080 | 148/18723 | 2.66e-12 | 4.75e-10 | 34 |
GO:00064179 | Breast | Precancer | regulation of translation | 67/1080 | 468/18723 | 4.71e-12 | 7.64e-10 | 67 |
GO:00003759 | Breast | Precancer | RNA splicing, via transesterification reactions | 52/1080 | 324/18723 | 1.74e-11 | 2.22e-09 | 52 |
GO:00003779 | Breast | Precancer | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 51/1080 | 320/18723 | 3.55e-11 | 4.04e-09 | 51 |
GO:00003989 | Breast | Precancer | mRNA splicing, via spliceosome | 51/1080 | 320/18723 | 3.55e-11 | 4.04e-09 | 51 |
GO:00480249 | Breast | Precancer | regulation of mRNA splicing, via spliceosome | 22/1080 | 101/18723 | 5.29e-08 | 3.18e-06 | 22 |
GO:19033118 | Breast | Precancer | regulation of mRNA metabolic process | 38/1080 | 288/18723 | 1.63e-06 | 5.97e-05 | 38 |
GO:00506848 | Breast | Precancer | regulation of mRNA processing | 23/1080 | 137/18723 | 3.49e-06 | 1.13e-04 | 23 |
GO:00331199 | Breast | Precancer | negative regulation of RNA splicing | 9/1080 | 25/18723 | 6.03e-06 | 1.72e-04 | 9 |
GO:19033129 | Breast | Precancer | negative regulation of mRNA metabolic process | 16/1080 | 92/18723 | 6.70e-05 | 1.35e-03 | 16 |
GO:00480255 | Breast | Precancer | negative regulation of mRNA splicing, via spliceosome | 6/1080 | 20/18723 | 6.99e-04 | 8.43e-03 | 6 |
GO:00064039 | Breast | Precancer | RNA localization | 23/1080 | 201/18723 | 1.34e-03 | 1.41e-02 | 23 |
GO:19908303 | Breast | Precancer | cellular response to leukemia inhibitory factor | 13/1080 | 94/18723 | 2.83e-03 | 2.49e-02 | 13 |
GO:19908233 | Breast | Precancer | response to leukemia inhibitory factor | 13/1080 | 95/18723 | 3.11e-03 | 2.64e-02 | 13 |
GO:00506865 | Breast | Precancer | negative regulation of mRNA processing | 6/1080 | 29/18723 | 5.49e-03 | 4.01e-02 | 6 |
GO:000838014 | Breast | IDC | RNA splicing | 73/1434 | 434/18723 | 1.27e-10 | 1.57e-08 | 73 |
GO:004348414 | Breast | IDC | regulation of RNA splicing | 36/1434 | 148/18723 | 3.32e-10 | 3.77e-08 | 36 |
GO:000037514 | Breast | IDC | RNA splicing, via transesterification reactions | 58/1434 | 324/18723 | 9.44e-10 | 9.58e-08 | 58 |
GO:000037714 | Breast | IDC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 57/1434 | 320/18723 | 1.60e-09 | 1.49e-07 | 57 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F7 | SNV | Missense_Mutation | novel | c.308N>A | p.Ser103Tyr | p.S103Y | P08709 | protein_coding | tolerated(0.17) | benign(0.028) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
F7 | SNV | Missense_Mutation | | c.729N>G | p.Ile243Met | p.I243M | P08709 | protein_coding | deleterious(0.04) | benign(0.157) | TCGA-AN-A0AM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F7 | SNV | Missense_Mutation | novel | c.1132N>A | p.Gly378Arg | p.G378R | P08709 | protein_coding | tolerated(0.22) | benign(0) | TCGA-AR-A2LJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
F7 | SNV | Missense_Mutation | rs749760143 | c.973N>A | p.Glu325Lys | p.E325K | P08709 | protein_coding | tolerated(0.05) | probably_damaging(0.933) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
F7 | insertion | Frame_Shift_Ins | novel | c.731_732insGGGAAAATGGGCAGGTCAGC | p.Asn244LysfsTer28 | p.N244Kfs*28 | P08709 | protein_coding | | | TCGA-AN-A0AM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F7 | insertion | Frame_Shift_Ins | novel | c.757_758insGCAA | p.His253ArgfsTer29 | p.H253Rfs*29 | P08709 | protein_coding | | | TCGA-BH-A0HY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | taxotere | CR |
F7 | insertion | In_Frame_Ins | novel | c.759_760insCCCAAGGCCGAATTGTGGGGGGCAAGG | p.His253_Cys254insProLysAlaGluLeuTrpGlyAlaArg | p.H253_C254insPKAELWGAR | P08709 | protein_coding | | | TCGA-BH-A0HY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | taxotere | CR |
F7 | SNV | Missense_Mutation | | c.475N>C | p.Glu159Gln | p.E159Q | P08709 | protein_coding | deleterious(0.04) | benign(0.115) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
F7 | SNV | Missense_Mutation | novel | c.348N>C | p.Gln116His | p.Q116H | P08709 | protein_coding | deleterious(0.02) | probably_damaging(0.961) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
F7 | SNV | Missense_Mutation | | c.160N>A | p.Val54Ile | p.V54I | P08709 | protein_coding | tolerated(0.2) | benign(0.01) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Vatreptacog alfa (activated) | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Factor viia | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Recombinant factor VIIa PEGylated liposomal | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | F-7TG | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | BAX-817 | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | inhibitor | 178103166 | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | CB-813 | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Activated recombinant FVII-albumin fusion protein | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | inhibitor | 252166701 | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Eptacog alfa intravenous | | |